# Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

> **NCT00980174** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 242 (actual)

## Conditions studied

- Low Bone Mass
- Low Bone Mineral Density
- Males With Osteoporosis
- Osteopenia
- Osteoporosis

## Interventions

- **DRUG:** 60 mg denosumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00980174
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-01
- **Primary completion:** 2011-06-21
- **Final completion:** 2012-05-23
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00980174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00980174, "Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00980174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*